2012 Fierce 15 arrives today; A look back...

It's almost the moment many of us at FierceBiotech have been waiting for. Editor-in-Chief John Carroll will announce the 2012 Fierce 15 list of promising biotech companies this morning at the BioPharm America (BPA) conference in Boston. We'll be sharing the full list with profiles on each of the 15 companies tomorrow morning on our website and via our Wednesday newsletter edition of FierceBiotech. Folks can also follow some of the action tomorrow morning on Twitter, where members of our staff will be sharing names of companies on this year's list and hopefully a few photos from the ceremonies in Boston.

Every year we hunt for 15 outstanding privately held biotech groups to feature for Fierce 15, and it's interesting to see how the companies mature and adapt to the myriad challenges of the biopharma industry. Can you guess which two 2011 Fierce 15 companies have completed IPOs since we announced the list last September? You'll find them, of course, in last year's report as well as others from as far back as 2007. Enjoy the trip down memory lane and stay tuned for tomorrow's news. And if you're at BPA, Carroll will be announcing the 2012 Fierce 15 during the opening remarks session from 10:15 a.m. to 11 a.m. ET tomorrow. -- Ryan McBride (Email | Twitter)

  • FierceBiotech's 2011 Fierce 15
  • FierceBiotech's 2010 Fierce 15
  • FierceBiotech's 2009 Fierce 15
  • FierceBiotech's 2008 Fierce 15
  • FierceBiotech's 2007 Fierce 15

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.